Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer

Wuerstlein, R; Ellis, P; Montemurro, F; Torres, AA; Delaloge, S; Zhang, Q; Wang, X; Wang, S; Shao, Z; Li, H; Rachman, A; Vongsaisuwon, M; Liu, H; Fear, S; Pena-Murillo, C; Barrios, C

Wuerstlein, R (通讯作者)，Univ Hosp Munich, Breast Ctr, Dept Obstet & Gynecol, Marchioninistr 15, D-81377 Munich, Germany.;Wuerstlein, R (通讯作者)，LMU, CCC Munich, Marchioninistr 15, D-81377 Munich, Germany.

ESMO OPEN, 2022; 7 (5):

Abstract

Background: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-pos......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索